遠大醫藥(00512.HK):獲得乾眼症新藥的開發及商業化權利
格隆匯1月5日丨遠大醫藥(00512.HK)公佈,集團近日與全福生技訂立授權協議,據此集團獲得全福生技開發的全球首創治療乾眼症的產品BRM421及相關技術的大中華地區的開發及商業化權利。同時,集團亦與全福生技訂立股份認購協議,據此集團將會認購全福生技的少部分股份,並將有權爭取委任一個董事席次(受限於全福生技的股東於股東會中批准)。
根據授權協議的約定,自訂立授權協議日起集團將獲得BRM421在大中華地區的二十年獨家開發和商業化權利,並進行產品技術轉移,實現產品本地化生產。集團將根據開發進度及銷售情況分階段向全福生技支付授權首付款及里程碑款項,並根據BRM421的銷售金額年度淨額支付若干比例的權利金。
BRM421為全球創新的小分子多肽滴眼液產品,可加速角膜緣幹細胞的分裂增殖,促進眼表修復以治療乾眼症。產品目前已於美國進行2期臨牀研究,安全性高及刺激性小,具有能夠在兩星期內迅速緩解乾眼症症狀和體徵的潛力。產品計劃在2020年初開展更大規模的臨牀研究以支持推出市場。
集團作為中國最大的眼科藥研發、生產及銷售綜合企業之一,一直致力於眼科領域新產品的開發及引進。此次與全福生技的合作,不僅為集團在眼科板塊引進了首個全球創新的乾眼症產品,進一步豐富了板塊中高創新壁壘的產品線,為本集團的長期發展提供戰略儲備。同時,對全福生技的股權投資也為深入合作及產品開發提供基礎,充分利用其管理層和核心研發團隊豐富的大型企業管理和研發經驗,為新產品的開發提供技術支援。
集團一直高度重視創新產品的研發,積極參與核心治療領域之優質產品和資產的全球投資併購及拓展等活動,籍此獲得豐富的產品線佈局和重磅產品儲備。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.